Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency
Portfolio Pulse from
Korro has received Australian HREC approval and CTN clearance to begin a Phase 1/2a clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency. The study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of KRRO-110.
November 21, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Korro has received regulatory approval in Australia to start a clinical trial for KRRO-110, which could positively impact the company's stock if the trial shows promising results.
The approval to start a clinical trial is a significant step for Korro, as it allows the company to advance its drug development process. Positive outcomes from the trial could lead to further development and potential market approval, which would be beneficial for the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90